BiotechTube
Vertanical

Vertanical

Berlin, Germany· Est.
vertanical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Vertanical is a clinical-stage biopharma company pioneering cannabinoid-based treatments for chronic pain. Its lead candidate, VER-01, is in late-stage development for chronic low back pain, with a marketing application submitted in Germany, and has additional planned programs for osteoarthritis and painful diabetic neuropathy. The company operates an advanced GMP manufacturing facility and runs a robust clinical program across Europe and the US, positioning itself as a potential disruptor in the global pain management market, which affects over a billion people.

Chronic PainChronic Low Back PainOsteoarthritisPainful Diabetic Peripheral Neuropathy

Technology Platform

Proprietary development and GMP manufacturing of a unique cannabinoid-based pharmaceutical designed to treat chronic pain and associated symptoms like sleep disorders and depression.

Opportunities

The global chronic pain market represents a multi-billion dollar opportunity with significant unmet need due to the limitations and side effects of current therapies like opioids.
Vertanical's cannabinoid-based therapy, VER-01, which aims to treat both pain and associated comorbidities, could capture substantial market share if it demonstrates a superior safety and efficacy profile.
Regulatory approval in Germany would provide a crucial beachhead in Europe for future expansion.

Risk Factors

Key risks include regulatory rejection or delay for VER-01, particularly given its cannabinoid basis which may face stricter scrutiny.
Clinical trials for new indications (OA, PDPN) may fail to meet endpoints, and the company faces intense competition in the pain management space.
As a pre-revenue private company, Vertanical also carries significant financial and execution risk in scaling manufacturing and commercialization.

Competitive Landscape

Vertanical competes in the large and fragmented chronic pain market, facing competition from generic and branded opioids, NSAIDs, antidepressants, anticonvulsants, and other novel non-opioid therapies. Its direct competitors include other companies developing cannabinoid-based pharmaceuticals (e.g., Jazz Pharmaceuticals' Epidiolex for other indications, GW Pharmaceuticals legacy) and novel analgesic mechanisms. Differentiation will rely on VER-01's holistic efficacy profile and safety data versus opioids.

More companies in Small Molecule Drugs →More companies in Germany →